VANFLYTA Tablet Post-marketing Surveillance Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080224910

Enrollment

210

Registered

2019-10-10

Start date

2019-10-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or refractory acute myeloid leukemia with FLT3-ITD mutation positive

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who start receiving VANFLYTA Tablet during the registration period.

Exclusion criteria

Exclusion criteria: Patients with a previous history of hypersensitivity to the ingredients of VANFLYTA.

Design outcomes

Primary

Measure	Time frame
safety Information about the adverse events that have occurred, by adverse reaction/infection category. Information about the safety specifications concerns that have occurred.	—

Secondary

Measure	Time frame
efficacy Best antitumor response	—

Countries

Japan

Contacts

Public ContactContact for GPSP

DAIICHI SANKYO CO., LTD.

contact_gpsp_jp@daiichisankyo.com+81-3-6225-1059

Outcome results